SPECTRAL ANNOUNCES PRESENTATIONS BY KEY OPINION LEADERS AT THE CRITICAL CARE CANADA FORUM

Toronto, Ontario, October 26, 2015 – Spectral Medical Inc., **("Spectral" or the "Company") (TSX: EDT) (OTC QX: EDTXF),** a Phase III company developing the first treatment for patients with septic shock that comprises a therapeutic device guided by a companion diagnostic, today announced that during the current Critical Care Canada Forum ("CCCF") Dr. P. Dellinger, the principal investigator of its EUPHRATES trial, will report on the status of this very important pivotal study . At the same conference, Professor Claudio Ronco, a world renowned authority on extracorporeal therapies for acute patients, will discuss the substantial evidence from clinical trials performed outside of North America supporting the extracorporeal removal of endotoxin as an adjunctive therapy for septic shock patients.

Spectral is now in the later stages of its own Phase III registration trial for Toraymyxin^{tm} as it seeks FDA approval for this medical device in the United States.

Schedule of Presentations – Monday, October 26, 2015:

11:20 - 11:35 AM	"The Euphrates Trial", Dr. - P. Dellinger
4:30 - 4:50 PM	"Detecting and Removing Endotoxin", Professor Claudio Ronco

To download the full program, visit the CCCF's website at www. criticalcarecanada.com

About Critical Care Canada Forum

The **Critical Care Canada Forum** (October 25–28, 2015, Sheraton Centre Toronto Hotel) is a 3-day conference focusing on topics that are relevant to the individuals involved with the care of critically ill patients, wherever the patients are located. Internationally recognized, the Critical Care Canada Forum focuses on leading-edge science through informative and interactive sessions, outstanding international faculty, poster presentations and more than 50 exhibits with the latest products and services for the critical care professional.

About Spectral Medical Inc.

Spectral is a Phase III company seeking U.S. FDA approval for its lead theranostics product for the treatment of endotoxemic septic shock. PMX is a therapeutic hemoperfusion device that removes endotoxin, a main trigger of sepsis, from the bloodstream. Directed by the Company's Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis, Spectral's EUPHRATES trial is the world's only active and most innovative Phase III study for a medical device in the area of septic shock.

PMX has been approved for therapeutic use in Japan and Europe, and has been used on more than 150,000 patients to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for PMX, and in November 2010, signed an exclusive distribution agreement for this product in Canada. Over 350,000 patients are diagnosed with septic shock in North America each year, representing a greater than $3 billion market opportunity for Spectral.

Spectral is listed on the Toronto Stock Exchange under the symbol EDT, and on the OTCQX under the symbol EDTXF. For more information please visit www.spectraldx.com

Forward-looking Statements

Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral's senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected.

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement

For further information please contact:

Anthony Businskas
Executive Vice President and CFO
Spectral Medical Inc.
416-626-3233 ext. 2200
tbusinskas@spectraldx.com

Ali Mahdavi
Capital Markets &Investor Relations
416-962-3300
am@spinnakercmi.com